Market Cap (In USD)
196.02 Million
Revenue (In USD)
6.03 Million
Net Income (In USD)
-63.07 Million
Avg. Volume
4.01 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.37-2.105
- PE
- -3.36
- EPS
- -0.2
- Beta Value
- 3.766
- ISIN
- US67577C1053
- CUSIP
- 67577C105
- CIK
- 1372299
- Shares
- 292014000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shankar Musunuri M.B.A., Ph.D.
- Employee Count
- -
- Website
- https://www.ocugen.com
- Ipo Date
- 2014-12-03
- Details
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
More Stocks
-
SPARC
-
NAVB
-
KAMDHENUKamdhenu Limited
KAMDHENU
-
CAECAE Inc.
CAE
-
WNS
-
LBRTLiberty Energy Inc.
LBRT
-
6730AXELL Corporation
6730
-
7826